Found: 56
Select item for more details and to access through your institution.
Measurable residual disease in multiple myeloma: ready for clinical practice?
- Published in:
- Journal of Hematology & Oncology, 2020, v. 13, n. 1, p. 1, doi. 10.1186/s13045-020-00911-4
- By:
- Publication type:
- Article
Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms.
- Published in:
- Journal of Clinical Investigation, 2005, v. 115, n. 9, p. 2351, doi. 10.1172/JCI24177
- By:
- Publication type:
- Article
CAR T-Cells in Multiple Myeloma Are Ready for Prime Time.
- Published in:
- Journal of Clinical Medicine, 2020, v. 9, n. 11, p. 3577, doi. 10.3390/jcm9113577
- By:
- Publication type:
- Article
Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1‐acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 3, p. 522, doi. 10.1111/bjh.16788
- By:
- Publication type:
- Article
Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.
- Published in:
- British Journal of Haematology, 2017, v. 179, n. 1, p. 66, doi. 10.1111/bjh.14821
- By:
- Publication type:
- Article
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
- Published in:
- British Journal of Haematology, 2017, v. 178, n. 4, p. 547, doi. 10.1111/bjh.14708
- By:
- Publication type:
- Article
A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.
- Published in:
- British Journal of Haematology, 2015, v. 170, n. 6, p. 804, doi. 10.1111/bjh.13500
- By:
- Publication type:
- Article
Expression of p53 protein isoforms predicts survival in patients with multiple myeloma.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 6, p. 700, doi. 10.1002/ajh.26507
- By:
- Publication type:
- Article
Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138<sup>++</sup> and CD138<sup>low</sup> Subpopulations in Multiple Myeloma Cell Lines.
- Published in:
- PLoS ONE, 2014, v. 9, n. 3, p. 1, doi. 10.1371/journal.pone.0092378
- By:
- Publication type:
- Article
Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects.
- Published in:
- PLoS ONE, 2012, v. 7, n. 4, p. 1, doi. 10.1371/journal.pone.0034914
- By:
- Publication type:
- Article
Deficient Spindle Assembly Checkpoint in Multiple Myeloma.
- Published in:
- PLoS ONE, 2011, v. 6, n. 11, p. 1, doi. 10.1371/journal.pone.0027583
- By:
- Publication type:
- Article
Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma.
- Published in:
- Cancers, 2021, v. 13, n. 19, p. 4924, doi. 10.3390/cancers13194924
- By:
- Publication type:
- Article
Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial.
- Published in:
- Cancers, 2020, v. 12, n. 12, p. 3615, doi. 10.3390/cancers12123615
- By:
- Publication type:
- Article
Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment.
- Published in:
- Clinical Lymphoma & Myeloma, 2008, v. 8, n. 6, p. 352
- By:
- Publication type:
- Article
Molecular Characterization of Complete and Incomplete Immunoglobulin Heavy Chain Gene Rearrangements in Hairy Cell Leukemia.
- Published in:
- Clinical Lymphoma & Myeloma, 2007, v. 7, n. 9, p. 573
- By:
- Publication type:
- Article
RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 1, p. 200, doi. 10.1007/s10637-012-9845-3
- By:
- Publication type:
- Article
Efficacy and safety of pegylated liposomal doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2011, v. 11, n. 1, p. 38, doi. 10.3816/CLML.2010.n.120
- By:
- Publication type:
- Article
Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on Outcome.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2011, v. 11, n. 1, p. 44, doi. 10.3816/CLML.2011.n.005
- By:
- Publication type:
- Article
Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma.
- Published in:
- European Journal of Haematology, 2012, v. 89, n. 4, p. 328, doi. 10.1111/ejh.12000
- By:
- Publication type:
- Article
Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.
- Published in:
- European Journal of Haematology, 2012, v. 89, n. 1, p. 16, doi. 10.1111/j.1600-0609.2012.01788.x
- By:
- Publication type:
- Article
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
- Published in:
- European Journal of Haematology, 2011, v. 86, n. 1, p. 23, doi. 10.1111/j.1600-0609.2010.01533.x
- By:
- Publication type:
- Article
P53 deletion may drive the clinical evolution and treatment response in multiple myeloma.
- Published in:
- European Journal of Haematology, 2010, v. 84, n. 4, p. 359, doi. 10.1111/j.1600-0609.2009.01399.x
- By:
- Publication type:
- Article
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.
- Published in:
- European Journal of Haematology, 2009, v. 82, n. 6, p. 426, doi. 10.1111/j.1600-0609.2009.01257.x
- By:
- Publication type:
- Article
Medium-term results of percutaneous vertebroplasty in multiple myeloma.
- Published in:
- European Journal of Haematology, 2006, v. 77, n. 1, p. 7, doi. 10.1111/j.0902-4441.2005.t01-1-EJH2355.x
- By:
- Publication type:
- Article
Bortezomib is an efficient agent in plasma cell leukemias.
- Published in:
- International Journal of Cancer, 2005, v. 114, n. 4, p. 665, doi. 10.1002/ijc.20793
- By:
- Publication type:
- Article
P-224: Pomalidomide, bortezomib, and dexamethasone after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): A safety subanalysis of the phase 3 OPTIMISMM trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S163, doi. 10.1016/S2152-2650(21)02351-X
- By:
- Publication type:
- Article
P-178: Impact of t(11;14) according to induction regimen in newly diagnosed transplant-eligible multiple myeloma patients: long term follow-up of GEM05MENOS65 and GEM2012 PETHEMA/GEM studies.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S134, doi. 10.1016/S2152-2650(21)02305-3
- By:
- Publication type:
- Article
P-193: Elotuzumab plus pomalidomide/dexamethasone for relapsed/refractory multiple myeloma: final overall survival from the phase 2 ELOQUENT-3 trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S143, doi. 10.1016/S2152-2650(21)02320-X
- By:
- Publication type:
- Article
OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S3, doi. 10.1016/S2152-2650(21)02079-6
- By:
- Publication type:
- Article
Allogeneic mesenchymal stem cell therapy for refractory cytopenias after hematopoietic stem cell transplantation.
- Published in:
- Transfusion, 2012, v. 52, n. 5, p. 1086, doi. 10.1111/j.1537-2995.2011.03400.x
- By:
- Publication type:
- Article
Authors' Response.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 8, p. 146, doi. 10.1002/ajh.24079
- By:
- Publication type:
- Article
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 4, p. 314, doi. 10.1002/ajh.23933
- By:
- Publication type:
- Article
Expression of Bcl-2 by human bone marrow mast cells and its overexpression in mast cell leukemia.
- Published in:
- American Journal of Hematology, 1999, v. 60, n. 3, p. 191, doi. 10.1002/(SICI)1096-8652(199903)60:3<191::AID-AJH4>3.0.CO;2-Y
- By:
- Publication type:
- Article
Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.
- Published in:
- Journal of Hematology & Oncology, 2017, v. 10, p. 1, doi. 10.1186/s13045-017-0495-y
- By:
- Publication type:
- Article
Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development.
- Published in:
- Journal of Hematology & Oncology, 2016, v. 9, p. 1, doi. 10.1186/s13045-016-0343-5
- By:
- Publication type:
- Article
Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial
- Published in:
- British Journal of Haematology, 2011, v. 153, n. 2, p. 212, doi. 10.1111/j.1365-2141.2011.08569.x
- By:
- Publication type:
- Article
Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells.
- Published in:
- British Journal of Haematology, 2010, v. 148, n. 1, p. 110, doi. 10.1111/j.1365-2141.2009.07929.x
- By:
- Publication type:
- Article
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.
- Published in:
- British Journal of Haematology, 2008, v. 143, n. 4, p. 511, doi. 10.1111/j.1365-2141.2008.07378.x
- By:
- Publication type:
- Article
The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
- Published in:
- British Journal of Haematology, 2008, v. 141, n. 4, p. 470, doi. 10.1111/j.1365-2141.2008.07049.x
- By:
- Publication type:
- Article
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
- Published in:
- British Journal of Haematology, 2007, v. 137, n. 5, p. 429, doi. 10.1111/j.1365-2141.2007.06585.x
- By:
- Publication type:
- Article
Functional class switch recombination may occur 'in vivo' in Waldenström macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2007, v. 136, n. 1, p. 114, doi. 10.1111/j.1365-2141.2006.06397.x
- By:
- Publication type:
- Article
Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft- versus-host disease after allogeneic transplantation.
- Published in:
- British Journal of Haematology, 2005, v. 130, n. 3, p. 394, doi. 10.1111/j.1365-2141.2005.05614.x
- By:
- Publication type:
- Article
Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents.
- Published in:
- British Journal of Haematology, 2003, v. 123, n. 5, p. 858, doi. 10.1046/j.1365-2141.2003.04706.x
- By:
- Publication type:
- Article
Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation.
- Published in:
- British Journal of Haematology, 2003, v. 121, n. 1, p. 104, doi. 10.1046/j.1365-2141.2003.04237.x
- By:
- Publication type:
- Article
Reply to Yanamandra et al.
- Published in:
- British Journal of Haematology, 2003, v. 120, n. 6, p. 1096, doi. 10.1046/j.1365-2141.2003.04208_6.x
- By:
- Publication type:
- Article
Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival.
- Published in:
- British Journal of Haematology, 2002, v. 118, n. 4, p. 1034, doi. 10.1046/j.1365-2141.2002.03749.x
- By:
- Publication type:
- Article
Methylenetetrahydrofolate reductase genotype does not play a role in multiple myeloma pathogenesis.
- Published in:
- British Journal of Haematology, 2002, v. 117, n. 4, p. 890, doi. 10.1046/j.1365-2141.2002.03502.x
- By:
- Publication type:
- Article